drugset / Trial / NCT02366325
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety,efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic kidney disease (CKD) who are on hemodialysis.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegmolesatide | Peptide | 0.025 mg/kg | Intravenous |
| Subject | Pegmolesatide | Peptide | 0.05 mg/kg | Intravenous |
| Subject | Pegmolesatide | Peptide | 0.08 mg/kg | Intravenous |